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Summary
 Background: The role of Barrett esophagus in carcinogenesis is widely accepted, but the signiﬁ cance of esopha-
geal columnar mucosa without histological intestinal metaplasia, known as columnar-lined esoph-
agus, is debated.
 Material/Methods: We studied 128 patients free of Helicobacter pylori with reﬂ ux-related symptoms and columnar mu-
cosa in the esophagus at endoscopy, 106 patients with Barrett esophagus (referred to as the Barrett 
group) and 22 patients without intestinal metaplasia (columnar group). Samples from 20 subjects 
free of H. pylori were used as controls. Immunostaining for keratin 7 (KRT7), keratin 20 (KRT20), 
caudal type homeobox 2 (CDX2), mucin 2, oligomeric mucus/gel-forming (MUC2), and tumor 
protein p53 (TP53) was assessed.
 Results: Samples taken 1 cm above the gastroesophageal junction showed KRT7 staining in all cases in the 
Barrett and columnar groups and none in the control group. Immunostaining for TP53 was ab-
sent in the control group, and more frequent in the columnar group (7, 31.8%) compared with 
the Barrett group (14, 13.2%, P=0.033). In the columnar group, low grade dysplasia and TP53 ex-
pression was seen in 7 of 22 biopsy specimens (31.8%) at baseline and in 4 additional specimens 
after 2 years, for a total of 11 specimens (50.0%).
 Conclusions: The expression of KRT7 might help to explain the pathological, reﬂ ux-related nature of colum-
nar-lined esophagus, as aberrant expression in a very early stage of the multistep Barrett esopha-
gus progression. Expression of KRT7 may occur in basal glandular cells as a result of their multi-
potentiality and susceptibility to immunophenotype changes induced by reﬂ ux.
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BACKGROUND
Traditionally, Barrett esophagus was deﬁ ned by the pres-
ence of at least 2 to 3 cm of columnar epithelium in the 
lower esophagus, whereas in recent literature, Barrett mu-
cosa is deﬁ ned as endoscopic ﬁ ndings of columnar muco-
sa of any length above the gastroesophageal junction (Z 
line) and histological ﬁ ndings of intestinal metaplasia with 
“goblet cells” [1].
In clinical practice at times, endoscopic and histological 
ﬁ ndings may not agree, for example, when a biopsy speci-
men from the distal esophagus shows either cardiac or fun-
dic mucosa without intestinal metaplasia and cannot there-
fore be deﬁ ned as Barrett mucosa [2].
Hereafter, we refer to this as columnar-lined esophagus.
Until recently, not enough attention has been dedicated to 
columnar-lined esophagus. The absence of goblet cells in 
endoscopically evident Barrett mucosa has been considered 
a function of sampling error [3] that could be reduced by 
increasing the number of biopsies at the initial diagnostic 
endoscopy [4], by repeating the sampling, and by assessing 
more sections histologically.
Nevertheless, the combination of endoscopic ﬁ ndings of 
columnar mucosa and the histologic absence of intestinal 
metaplasia poses clinical challenges, since the condition 
cannot be deﬁ ned as Barrett esophagus and, without clear 
guidelines for clinical management, follow-up will not com-
monly be obtained on these patients.
Some authors [5–7] have reported the utility of the pattern 
of keratin 7 (KRT7) and keratin 20 (KRT20) to distinguish 
Barrett metaplasia from cardiac intestinal metaplasia, that is, 
fundic and/or cardiac mucosa with intestinal metaplasia with-
out endoscopic evidence of Barrett esophagus. No consensus 
exists, however, regarding the reproducibility of the deep to 
superﬁ cial pattern of KRT7 and KRT20 in Barrett esophagus 
and its utility in the differential diagnosis of Barrett metapla-
sia and cardiac intestinal metaplasia [8–10]. Moreover, the 
immunostaining expression of KRT7 and KRT20 in colum-
nar-lined esophagus has still to be fully described.
Caudal type homeobox 2 (CDX2), an intestinal-speciﬁ c ho-
meobox gene known to play a critical role in the differen-
tiation and maintenance of intestinal epithelial functions, 
has been observed in 30% to 38% of patients with cardiac 
epithelium without goblet cells and in all patients with in-
testinal metaplasia [11,12]. Therefore, it has been suggest-
ed that CDX2 might be useful for identifying patients with 
Barrett metaplasia when no goblet cells are visible [12].
The aim of this study was to better understand the histoge-
netic and prognostic meaning of columnar-lined esopha-
gus. We assessed KRT7, KRT20, and CDX2 immunostaining 
in biopsy specimens of columnar-lined esophagus from pa-
tients free from Helicobacter pylori, and compared the ﬁ nd-
ings to patients with Barrett esophagus and to controls. We 
also obtained follow-up, by using mapping combined with 
tumor protein p53 (TP53) assessment, as previous reports 
have described TP53 values in low grade Barrett dysplasia 
and correlation with disease progression [13–15].
MATERIAL AND METHODS
We studied a total of 148 individuals, 128 patients and 20 con-
trols. Written consent for studies participation was obtained 
from all patients. The study was approved by the ethic com-
mittee. We recruited 128 consecutive patients, who were free 
from H. pylori and with no history of previous H. pylori infec-
tion, who were found at endoscopy to have columnar muco-
sa extending from 1 cm to more than 3 cm above the gastro-
esophageal junction. These 128 patients formed 2 groups, 
106 patients (82.8%) with Barrett esophagus (referred to as 
the Barrett group) and 22 patients (17.2%) with columnar-
lined esophagus (referred to as the columnar group). For 
each patient in the columnar group, to exclude the possi-
bility of a sampling error, endoscopy with multiple biopsies 
was repeated after 2 months, without any change in the en-
doscopic and histological ﬁ ndings (data not shown). At the 
endoscopy the gastroesophageal junction was identiﬁ ed as 
the point at which the tubular esophagus changes to a sack-
like structure and the presence of hiatal hernia was assessed. 
The patients had been referred to the Esophageal Surgical 
Unit between January 2001 and May 2005 for evaluation of 
their suspected gastroesophageal reﬂ ux disease. All patients 
had 1 or more symptoms such as heartburn, regurgitation, 
dysphagia, otolaryngological symptoms, and asthma. All pa-
tients underwent 4-quadrant biopsies every 1 cm to 2 cm, 
depending on the length of the columnar-lined esophagus, 
and 1 biopsy below the gastroesophageal junction. Two more 
biopsies, one taken 1 cm below the gastroesophageal junc-
tion and one in the antrum, were performed for colorimet-
ric test and histological assessment of H. pylori.
The control group consisted of 20 individuals who were 
free from H. pylori, without gastroesophageal reﬂ ux disease 
symptoms and lacking endoscopic ﬁ ndings of both reﬂ ux 
esophagitis and columnar mucosa in the esophagus. The 
squamocolumnar junction corresponded to the location of 
the gastroesophageal junction in all patients in the control 
group. For the control group, only 1 sample was obtained 1 
cm below the gastroesophageal junction because only squa-
mous epithelium was present above this point.
All histological analyses were performed by 1 of the authors 
(C.D.), who was masked to group assignment when perform-
ing the histological analysis. Biopsies were ﬁ xed in 10% buff-
ered formalin and embedded in parafﬁ n; 5 μm sections were 
obtained at 5 different levels and stained with hematoxylin 
and eosin and Alcian periodic acid Schiff (PAS) stain, to 
facilitate the identiﬁ cation of goblet cells. Intestinal meta-
plasia was deﬁ ned as the presence of intestinal-type goblet 
cells stained blue with Alcian PAS stain.
Immunohistochemical studies were performed using the 
avidin-biotin-complex technique. The primary monoclonal 
antibodies used in this study were keratin 7 (KRT7, clone 
OV-TL12/30) and keratin 20 (KRT20, clone Ks 20.8), both 
obtained from Dako (Dako A/S, Glostrup, Denmark); and 
mucin 2, oligomeric mucus/gel-forming (MUC2), tumor 
protein p53 (TP53, clone DO7), and caudal type homeo-
box 2 (CDX2, clone AMT28), obtained from Novocastra 
Laboratories (Newcastle upon Tyne, United Kingdom).
Sections were cut from 10% formalin-ﬁ xed, parafﬁ n-embed-
ded materials, deparafﬁ nized in xylene, and rehydrated with 
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alcohols. Immunohistochemical assays were performed ac-
cording to the manufacturer’s instructions (Universal LSAAB 
kit, Dako). To improve the immunostaining results, samples 
were digested with 0.1% trypsin before incubation with KRT7, 
and microwaved in 10 mM citrate buffer (pH 6.0) before in-
cubation with KRT20, TP53, CDX2, and MUC2. As a positive 
control for KRT7, immunostaining was performed on sec-
tions of cholangiocarcinoma that had previously proved to 
be positive. As positive controls for MUC2, KRT20, CDX2, 
and TP53, immunostaining was carried out on sections of 
colon adenocarcinoma that had previously proved to be pos-
itive. Negative controls without primary antibodies were in-
cluded in each immunohistochemistry run.
We considered immunostaining positive for KRT7, KRT20, 
and MUC2 if there was at least focal cytoplasmic staining in 
more than 1 cardiac or fundic gland.
A nuclear staining pattern only was considered positive for 
CDX2 and TP53. All cases were reviewed by the 2 pathologists 
(D.C., F.A.), and only cases with interobserver agreement about 
low grade dysplasia were considered dysplastic. In keeping with 
previous reports on TP53 values and interobserver agreement 
in the diagnosis of low grade Barrett dysplasia and on corre-
lation with disease progression, the presence of at least focal 
TP53 expression was used to conﬁ rm low grade dysplasia.
For patients in the columnar group, follow-up was performed 
after 2 years by repeating endoscopy and multiple biopsies 
with histological and histochemical analysis, as previously 
described for the baseline observations.
Statistical analysis
Statistical analysis was performed using the non-parametric 
Mann-Whitney test for independent samples. Differences 
were considered statistically signiﬁ cant for P values <.05.
RESULTS
The 128 patients had mean age of 44 years (range 21–72). 
No differences were found regarding age, sex (males/fe-
males ratio: 1,5/1), smoking and alcohol use (about 60% 
and 10% of patients in the trhee groups, respectively). 
Moreover, no differences in type and duration of reﬂ ux 
symptoms were evidenced between the Barrett group and 
the Columnar group and no patients have been treated be-
fore for gastroesophageal reﬂ ux disease.
Control group
In all the subjects, free from H. pylori, no hiatal hernia was 
detected at endoscopy. All biopsies were obtained 1 cm 
below the gastroesophageal junction and showed normal 
PAS-positive fundic mucosa with no inﬂ ammation and no 
expression of KRT7, TP53, MUC2, and CDX2 (Table 1). 
Expression of KRT20 was low and focal only in the surface 
epithelium in 8 of 20 specimens (40.0%). Expression of 
KRT20 was not present in deep cardiac or fundic glands 
(Table 1, Figures 1A–C).
Barrett group
All the patients, free from H. pylori, showed the presence 
of hiatal hernia at endoscopy. In specimens obtained 1 cm 
above the gastroesophageal junction, expression of KRT7 
was present in glands and surface epithelium in all cases 
(100%; Table 1). Expression of KRT20 was present in surface 
epithelium in 90 of 106 cases (84.9%) and in deep glands 
in only 15 of 106 cases (14.2%). Fourteen cases (13.2%) 
showed low grade dysplasia and expression of TP53 in co-
lumnar surface and gland epithelium. All the cases showed 
focal nuclear CDX2 expression in the glands, 45 (42,4%) 
of which showed CDX2 expression both in the glands and 
in the columnar surface epithelium. Expression of MUC2 
was present in the cytoplasm of the goblet cells.
The biopsies performed 1 cm below the gastroesophage-
al junction showed no intestinal metaplasia. The expres-
sion of KRT7 was focal in the glands in 26 cases (24.5%, 
Table 2), 20 of which (18.8%)also showed KRT7 expres-
sion in surface epithelium. The expression of KRT20 was 
present on surface epithelium in 70 cases (66.0%) and fo-
cal in deep glands in only 17 cases (16.0%). No biopsy spec-
Barrett group (n=106) Columnar group (n=22) Control group (n=20)
Glands Surface Glands Surface Glands Surface
KRT7*  106 (100.0%)  106 (100.0%)  22 (100%)  18 (81.8%)  0  0
KRT20*  15 (14.2%)  90 (84.9%)  2 (9.1%)  19 (86.4%)  0  8 (40.0%)
TP53 and low grade dysplasia  14 (13.2%)  14 (13.2%)  7 (31.8%)  7 (31.8%)  0  0
CDX2  106 (100.0%)  45 (42.4%)  5 (22.7%)  5 (22.7%)  0  0
MUC2  106 (100.0%)  106 (100.0%)  0  0  0  0
Table 1.  Immunohistochemical fi ndings in specimens from above the gastroesophageal junction in the Barrett and columnar groups and below the 
gastroesophageal junction in the control groups.
Barrett group, patients with Barrett esophagus; columnar group, patients with columnar-lined esophagus (lacking intestinal metaplasia); control 
group, individuals without Barrett or columnar-lined esophagus. Please note that the specimens from patients in the Barrett and columnar group 
were obtained 1 cm above the gastroesophageal junction, and specimens from individuals in the control group were obtained 1 cm below the 
gastroesophageal junction.
Data are presented as number (percentage). * Focal positivity in more than one cardiac or fundic gland.
CDX2 – caudal type homeobox 2; KRT7 – keratin 7; KRT20 – keratin 20; MUC2 – mucin 2, oligomeric mucus/gel-forming; TP53 – tumor protein p53.
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imens 1 cm below the gastroesophageal junction showed 
MUC2, CDX2, or TP53.
Columnar group
All the patients, free from H. pylori, showed the presence 
of hiatal hernia at endoscopy. Of the 22 patients in the co-
lumnar group, the columnar mucosa extended for between 
2 cm and 3 cm in 10 patients (45.5%) and for less than 2 cm 
in 12 patients (54.5%). At histology, weak Alcian staining 
was present in a few columnar cells in 7 cases (30%) but 
intestinal-type goblet cells were absent in all specimens 
(Figures 1D,E). Specimens consisted of fundic mucosa 
in 5 of 22 patients (22.7%), fundic-cardiac mucosa in 10 
(45.5%), and cardiac mucosa in 7 (31.8%). Inﬂ ammation 
was absent in 9 of 22 specimens (40.1%); however, the mu-
cosa was atrophic in appearance.
By immunohistochemistry of specimens obtained 1 cm 
above the gastroesophageal junction, expression of KRT7 
was focal in glands epithelium in all cases, 18 of which 
(81.8%) also showed focal surface KRT7 expression. 
(Table 1; Figures 1F,G), and expression of KRT20 in sur-
face epithelium was present in 19 specimens (86.4%). 
Regarding KRT20 glandular immunostaining, there were 
no signiﬁ cant differences between the 3 groups in samples 
from either above or below the gastroesophageal junction 
(P>.05). However, surface epithelial KRT20 immunostaining 
was signiﬁ cantly higher in both the Barrett group (66.0%, 
P=.001) and the columnar group (86.4%, P=.002), com-
pared with the control group (40.0%).
TP53 was focally present in nuclei of columnar surface and 
gland epithelium in 7 specimens (31.8%) (Figures 1H,I). 
For TP53 immunostaining in glands, higher levels of TP53 
staining were seen in the columnar (31.8%) versus con-
trol groups (0%, P=.006) and the columnar (31.8%) ver-
sus Barrett groups (13.2%, P=.033); however, there was no 
signiﬁ cant difference in TP53 staining between the Barrett 
and control groups (13.2% versus 0%, P>.05).
Most of the glands with KRT7 and TP53 staining showed 
low grade dysplasia, type II or hyperplastic dysplasia (16), 
consisting of mild branching (Figure 1F), pale and incon-
spicuous cytoplasm of the columnar cells, decreased cyto-
plasmic mucus production, and enlarged, rounded, vesic-
ular nuclei with evident nucleoli. Inﬂ ammation was often 
absent (Figures 2A,B). Figure 2C shows TP53 immunos-
taining in nuclei of glandular cells. In contrast, Figure 2D 
shows a morphologically normal gland present in the same 
specimen.
TP53 expression was focally present in the squamous basal 
layers of all the columnar and Barrett cases in which squa-
mous epithelium was evident.
In some cases, KRT7 expression was very focal and was lim-
ited to cystically dilated glands, often showing weak Alcian 
staining in a few columnar cells. In these cases, KRT7 ex-
pression was limited or more evident in the basal layer of 
the glandular epithelia (Figures 2E,F).
Five of 22 specimens (22.7%) in the columnar group showed 
CDX2 expression both in the columnar surface and gland 
epithelium from specimens taken above the gastroesopha-
geal junction.(3 of 5 being P53 positive at the same time). 
Figure 1.  (A–C) Specimen from control 
subject. Fundic mucosa, 1 cm below 
gastroesophageal junction, was devoid 
of intestinal metaplasia, infl ammation 
(Figure 1A, Alcian PAS stain, ×100), 
and KRT7 expression (Figure 1B, KRT7 
immunostaining, ×100). Focal superfi cial 
staining for KRT20 was present (Figure 
1C, KRT20 immunostaining, ×100). 
(D–I) Specimens from two subjects with 
columnar-lined esophagus (columnar 
group). Cardiac mucosa specimen was 
obtained 1 cm above gastroesophageal 
junction (Figure 1D–F–H refer to a 
case showing only PAS – staining 
glandular cells; Figure 1E–G–I refer 
to a case showing a few Alcian blue-
staining columnar cells). Figures 1D: 
Cardiac mucosa, showing PAS-staining 
glandular cells. Figure 1E: Cardiac mucosa 
showing a few Alcian blue-staining 
columnar cells, Infl ammation and clear 
goblet cells of intestinal metaplasia are 
absent in both (Figure 1D, Alcian PAS 
stain, ×200, Figure 1E; Alcian PAS stain, 
×100). Figures 1F–I: KRT7 and TP53 
immunostaining are evident in some 
glands that often are branching. Basal 
layers of squamous epithelium also show 
TP53 immunostaining. (Figure 1I on the 
left). Figure 1F, KRT7 immunostaining, 
×200; Figure 1G, KRT7 immunostaining, 
×100; Figure 1H, TP53 immunostaining, 
×200; Figure 1I, TP53 immunostaining, 
×100. KRT7 – keratin 7; KRT20 – keratin 
20; PAS – periodic acid Schiff ; TP53 – 
tumor protein p53.
A B C
D E F
G H I
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With regard to CDX2 immunostaining, statistical analysis 
showed a signiﬁ cant difference between the Barrett and con-
trol groups (100% versus 0%, P=.001) and between the co-
lumnar and control groups (22.7% versus 0%, P=.025).
The specimens in the columnar group lacked clear cyto-
plasmic MUC2 expression. A few cases showed weak Alcian 
blue staining in the apex of a small number of columnar 
cells and very weak apical staining for MUC2, but because 
staining was not evident in the cytoplasm, the specimens 
were considered negative. With regard to MUC2 cytoplas-
mic immunostaining in glands, a signiﬁ cant difference was 
found between the Barrett and columnar groups (100% 
versus 0%), and between the Barrett and control groups 
(100% versus 0%), but not between the columnar and con-
trol groups.
The biopsies performed 1 cm below the gastroesophage-
al junction did not show intestinal metaplasia. Expression 
of KRT7 was focally present both in surface and gland epi-
thelium in 3 of 22 specimens (13.6%, Table 2). There were 
no statistically signiﬁ cant differences in KRT7 staining be-
tween the Barrett and columnar group, and the columnar 
and control groups (P>.05). However, expression of KRT7 
was higher in the Barrett group compared with the control 
group (P=.013). Weak KRT20 expression was present on 
the surface epithelium in 19 of 22 specimens (86.4%) but 
not present in deep glands. No biopsy specimens from be-
low the gastroesophageal junction showed MUC2, CDX2, 
or TP53 immunostaining in the 3 groups. 
During the 2-year period, 8 patients (36.4%) in the colum-
nar group developed true Barrett as evidenced by the ap-
pearance of intestinal metaplasia and immunostaining for 
MUC2 and CDX2 (4 of which were associated with dyspla-
sia and TP53 staining). Figures 3A and 3B show baseline 
observations in a specimen of fundic mucosa with weak 
Alcian staining and focal KRT7 expression in a few colum-
nar cells with dilated glands, while Figures 3C–F show ob-
Barrett group (n=106) Columnar group (n=22) Control group* (n=20)
Gland Surface Gland Surface Gland Surface
KRT7  26 (24.5%)  20 (18.8%)  3 (13.6%)  3 (13.6%)  0  0
KRT20  17 (16.0%)  70 (66.0%)  0  19 (86.4%)  0  8 (40.0%)
TP53 and low grade dysplasia  0  0  0  0  0  0
CDX2  0  0  0  0  0  0
MUC2  0  0  0  0  0  0
Table 2. Immunohistochemical fi ndings in specimens from below the gastroesophageal junction in the Barrett, columnar, and control groups. 
Barrett group, patients with Barrett esophagus; columnar group, patients with columnar-lined esophagus (lacking intestinal metaplasia); control 
group,* individuals without Barrett or columnar-lined esophagus. Information presented here for the control group is the same as in Table 1. Please 
note that the specimens from all subjects were obtained 1 cm below the gastroesophageal junction.
Data are presented as number (percentage).
CDX2 – caudal type homeobox 2; KRT7 – keratin 7; KRT20 – keratin 20; MUC2 – mucin 2, oligomeric mucus/gel-forming; TP53 – tumor protein p53.
Figure 2.  Specimen from patient with columnar-
lined esophagus. (A–C) Low grade 
dysplasia, type II (hyperplastic dysplasia). 
The gland epithelium consists of 
columnar cells with enlarged, rounded, 
vesicular nuclei, evident nucleoli, 
inconspicuous cytoplasm (Figure 2A, 
hematoxylin & eosin stain, ×400), and 
small apical amounts of PAS-positive 
mucus (Figure 2B, Alcian PAS stain, 
×400). Infl ammation and intestinal 
metaplasia are absent. Nuclear 
staining for TP53 is present (Figure 
2C, TP53 immunostaining, ×400). 
(D) For contrast, note normal gland 
epithelium with small basal nuclei and 
abundant mucus-producing cytoplasm 
(hematoxylin & eosin stain, ×400). (E,F) 
Cystically dilated glands, showing weak 
Alcian blue staining in a few columnar 
cells (Figure 2E, Alcian PAS stain, ×200) 
and focal KRT7 staining (Figure 2F, KRT7 
immunostaining, ×200), more evident 
in the basal cell layer. KRT7 – keratin 7; 
PAS – periodic acid Schiff ; TP53 – tumor 
protein p53.
A B C D
E F
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servations at follow-up with the appearance of dysplasia, 
intestinal metaplasia, and diffuse KRT7 and TP53 immu-
nostaining.
In the follow-up a total of 13 specimens (59.1%) in the co-
lumnar group showed CDX2 nuclear expression, and a to-
tal of 11 specimens (50.0%) showed TP53 expression in 
dysplastic cells. The 2 latter conditions often occurred in-
dependently from the appearance of intestinal metaplasia 
and of MUC2 staining (Tables 3,4). 
DISCUSSION
Follow-up of patients with Barrett esophagus is strongly rec-
ommended since it has been universally accepted that Barrett 
adenocarcinoma does not arise de novo but follows an estab-
lished sequence from intestinal metaplasia through dyspla-
sia to adenocarcinoma. The presence of intestinal metapla-
sia with goblet cells has been considered the most signiﬁ cant 
change for the diagnosis of Barrett esophagus, a fact empha-
sized by the dictum “no goblets, no Barrett’s” [17].
Figure 3.  Specimen from patient with columnar-
lined esophagus. (A,B) Baseline 
observation: weak Alcian staining 
(Figure 3A, Alcian PAS stain, ×100) 
and very focal KRT7 staining (Figure 
3B, KRT7 immunostaining, ×100) in a 
few columnar cells present in cystically 
dilated glands. (C–F) Follow-up after 
2 years in the same patient, showing 
dysplasia (Figure 3C, hematoxylin & 
eosin, ×400), intestinal metaplasia 
(Figure 3D, Alcian PAS stain, ×400), 
diff use cytoplasmic KRT7 staining (Figure 
3E, KRT7 immunostaining, ×400), and 
nuclear TP53 immunostaining (Figure 
3F, TP53 immunostaining, ×400). 
The inserts in Figure 3C show nuclear 
changes and mitoses. KRT7 – keratin 7; 
PAS – periodic acid Schiff ; TP53 – tumor 
protein p53.
A B
C D
E F
IM/MUC2 CDX2– CDX2+ Total
Low grade dysplasia – TP53– 0  13  2  15 (67.8%)
Low grade dysplasia + TP53+ 0  4  3  7 (31.8%)
Total 0  17 (77.3%)  5 (22.7%)  22
Table 3. Baseline fi ndings of 22 patients with columnar – lined esophagus.
MUC2 – mucin 2, oligomeric mucus/gel-forming; CDX2 – caudal type homeobox 2; IM – intestinal metaplasia; TP53 – tumor protein p53.
IM/MUC2–
CDX2–
IM/MUC2+
CDX2+
IM/MUC2–
CDX2+ Total
Low grade dysplasia -TP53- 5 4 2  11 (50%)
Low grade dysplasia -TP53+ 4 4 3  11 (50%)
Total 9 8 5 22
CDX2– = 9 (40.9%) CDX2+ = 13 (59.1%)
Table 4. Two-year follow-up of 22 patients with columnar-lined esophagus. 
MUC2 – mucin 2, oligomeric mucus/gel-forming; CDX2 – caudal type homeobox 2; IM – intestinal metaplasia; TP53 – tumor protein p53.
Clinical Research Med Sci Monit, 2009; 15(5): CR203-210
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Consequently, despite endoscopic evidence of columnar 
mucosa, which can be extremely long and extend above 
the Z line in certain patients, the histological absence of 
goblet cells does not permit the pathologist to diagnose 
Barrett esophagus, and the hypothesis of a sampling error 
is put forward [3]. Moreover, the optimal management of 
such patients has not been clearly reported.
Several recent studies hypothesize the utility of CDX2 in the 
assessment of columnar-lined esophagus [12], that CDX2 
immunostaining might be useful for identifying patients 
with Barrett metaplasia when no goblet cells are found in 
biopsies from the columnar-lined esophagus. Nevertheless, 
the low percentage of CDX2-positive cases reported by pre-
vious studies, ranging from 30% [11] to 38% [12], leaves 
the problem of the diagnosis and management of a major-
ity of patients still unsolved.
Previous studies [5,6] have demonstrated the utility of KRT7 
and KRT20 in distinguishing Barrett metaplasia from cardiac 
intestinal metaplasia, whereas others have failed to conﬁ rm this 
claim [8–10]. Some authors state that the 2 conditions are virtu-
ally indistinguishable since they are biologically related [9]. To 
the best of our knowledge, the expression of KRT7 and KRT20 
in columnar-lined esophagus has still not been fully described. 
In keeping with previous studies [5,18,19], which report that 
normal cardiac and fundic glands do not stain for KRT7 and 
KRT20, and do not stain or only weakly stain for KRT20 in su-
perﬁ cial foveolar epithelium, in our study, we considered as 
positive all cases showing at least focal staining for KRT7 or 
KRT20 in more than 1 cardiac or fundic gland. With regard to 
KRT20, both in Barrett esophagus and columnar-lined esoph-
agus cases, more surface immunostaining was observed com-
pared with the control group, but there was no signiﬁ cant dif-
ference between the 3 groups in glandular KRT20 expression. 
For this reason, we will not further discuss KRT20.
Expression of KRT7 was similar in all cases of Barrett esoph-
agus and columnar-lined esophagus, with the same distri-
bution pattern consisting of KRT7 staining of surface epi-
thelium and both superﬁ cial and deep glands, as previously 
described in Barrett’s cases [5,6]. In contrast, the samples 
obtained 1 cm below the gastroesophageal junction in pa-
tients in the control group and in the majority of patients in 
the columnar and Barrett groups did not show KRT7 immu-
nostaining, in concordance with the previously-mentioned 
data regarding normal gastric glands [5,18,19]. These ob-
servations make it unlikely, at least for most of the colum-
nar-lined esophagus cases, that a sampling error is involved 
and support the hypothesis that columnar-lined esophagus, 
like Barrett esophagus, arises from multipotential stem cells 
in the esophagus and not from migration of gastric muco-
sa, which is immunohistochemically different.
We observed several specimens of columnar-lined esophagus 
consisting of fundic mucosa in which focal KRT7 staining was 
localized in cystically dilated glands (Figures 2F,G, 3A,B). Follow-
up showed the successive appearance of cardiac mucosa and 
intestinal metaplasia in some of these (Figure 3D). In agree-
ment with what has been previously suggested for “reﬂ ux car-
ditis” [20,21], these ﬁ ndings lead to the hypothesis that in cases 
of columnar-lined esophagus that are H. pylori-free, fundic mu-
cosa expressing KRT7 might also be an acquired reﬂ ux-related 
ﬁ nding, probably developing before “reﬂ ux carditis.”
This sequence from fundic mucosa with KRT7 staining in cys-
tically dilated glands to cardiac mucosa to intestinal-type mu-
cosa might be similar to the sequential morphological chang-
es described in the duodenogastric stoma of rats after surgery 
inducing duodenal-gastric reﬂ ux [22]. The absence of inﬂ am-
mation in 9 of 22 cases is in keeping with observations [23] that 
in reﬂ ux-related disease, intestinal metaplasia may develop as 
a result of the direct toxic effects of acid, nitrosamines, and 
bile without a primary role for inﬂ ammation. In our study, no 
patient had a history of H. pylori infection, so we can reason-
ably exclude a role for H. pylori in inducing KRT7. We could 
also hypothesize that KRT7, never present in normal fundic 
samples, is an aberrant expression, similar to that previously 
described for KRT20 expression in the extrahepatic bile tract 
[24]. It might represent a very early reﬂ ux-related stage, ear-
lier than CDX2 expression, in the multistep progression lead-
ing to Barrett metaplasia, according to the sequence: 
Columnar mucosa ® KRT7 ® CDX2 ® intestinal meta-
plasia ® dysplasia.
In our opinion, the validity of this sequence hypothesis is sup-
ported by the follow-up showing the subsequent appearance 
of intestinal metaplasia and CDX2 in 8 of 22 patients (36.4%) 
with columnar-lined esophagus, 4 of which also showed the 
appearance of low grade dysplasia and TP53 immunostain-
ing, in spite of the absence of intestinal metaplasia in the ﬁ rst 
biopsies. The features of low grade type II dysplasia raise the 
question of differential diagnosis with atypical regenerative 
changes. As regenerative changes are usually accompanied by 
inﬂ ammation, the histological changes that we observed, oc-
curring without inﬂ ammation but together with TP53 immu-
nostaining, suggest the presence of the so-called “low grade 
dysplasia type II” or “hyperplastic dysplasia” [16].
The meaning of non-goblet cells in the malignant transfor-
mation of Barrett esophagus is still debated [25–28].
With regard to intestinal metaplasia, our observations are 
in keeping with the statements of Tastuta and colleagues, 
[29] about the crucial role of CDX2 in directing intestinal-
type differentiation of the columnar cells of the esopha-
geal mucosa, since we found CDX2 expression in all Barrett 
esophagus cases.
Moreover, our MUC2 ﬁ ndings are in keeping with the ob-
servations of Chaves and colleagues [30], who reported 
that MUC2 expression “was restricted to Barrett’s cases 
and was more frequent in areas with intestinal metaplasia. 
Columnar-lined esophagus without intestinal metaplasia 
did not express MUC2.”
Nevertheless, we found that some columnar-lined esopha-
gus cases showed TP53 nuclear expression and low grade 
dysplasia, despite the absence of intestinal metaplasia and 
lack of MUC2 and CDX2 expression. These ﬁ ndings might 
indicate another hypothetical pathway consisting of: 
Columnar mucosa ® KRT7 ® dysplasia (TP53).
In keeping with Chaves and colleagues [30], it is notewor-
thy that the appearance of dysplasia and TP53 in follow-up 
was not always linked to the presence of MUC2 or CDX2 
expression or intestinal metaplasia.
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The KRT7 expression in the gland basal cells may indicate 
that these cells are more susceptible to the changes induced 
by a pathological reﬂ ux stimulus, due to their multipotenti-
ality. Furthermore, KRT7 expression is evident before CDX2 
and MUC2 expression, and independent of it.
As the distribution of goblet cells, considered indispens-
able for the diagnosis of Barrett esophagus, is patchy, we 
cannot say how many of the columnar-lined esophagus cas-
es represent underdiagnosis of Barrett esophagus because 
of insufﬁ cient sampling. Nevertheless, it could be hypoth-
esized that, as a marker of reﬂ ux-related damage in the 
columnar-lined esophagus devoid of goblet cells, KRT7 
expression may alert us to continue the long-term obser-
vation of patients who would not otherwise be followed. 
To the best of our knowledge, this is 1 of the ﬁ rst studies 
in which KRT7 expression is used not as an aid to differ-
entiate Barrett esophagus from cardiac intestinal meta-
plasia, but as an early marker of reﬂ ux-related damage, 
useful for reaching a clearer understanding of the true 
pathologic nature of H. pylori-free columnar-lined esoph-
agus. These preliminary results, reporting the presence of 
dysplasia associated with TP53 immunostaining in 50% of 
cases in a 2-year period, indicate that a surveillance pro-
gram should be suggested for such patients. A larger num-
ber of cases with longer follow-up must be studied to estab-
lish the risk of progression and the optimal management 
of these patients.
CONCLUSIONS
KRT7 is usually expressed in Columnar lining esophagus, 
despite the absence of intestinal metaplasia and MUC2 stain-
ing. KRT7 aberrant expression might help to understand 
the pathological, reﬂ ux-related nature of columnar lining 
oesophagus. Early CK7 expression is evident in the basal 
cells of the columnar epithelia, probably more susceptible 
to immunophenotype changes induced by a pathological 
reﬂ ux stimulus, due to their multi-potentiality. The pres-
ence of p53 and mild dysplasia in baseline biopsies and in 
two years follow-up biopsies suggests that columnar lining 
oesophagus may be involved in the multistep progression 
of Barrett’s Oesophagus.
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